CorVista Health

Executive Summary

CorVista Health is a private cardiovascular diagnostics company headquartered in San Francisco, founded in 2017. The company addresses the critical problem of misdiagnosis in cardiovascular diseases, where 69% of heart failure cases, 51% of pulmonary arterial hypertension cases, and 41% of heart attack patients with coronary artery disease are misdiagnosed or undiagnosed. CorVista is developing a non-invasive, point-of-care diagnostic platform that leverages advanced signal processing and machine learning to analyze cardiac hemodynamics from routine imaging. The technology aims to provide rapid, accurate, and accessible diagnoses across primary care and specialty settings, potentially reducing the time to treatment and improving outcomes for millions of patients. By targeting the largest causes of death worldwide with a scalable solution, CorVista has the potential to transform cardiovascular diagnostic workflows. The company is advancing through clinical validation and regulatory pathways. While specific funding and valuation details are not publicly disclosed, CorVista is positioned to capitalize on the growing demand for AI-driven diagnostics and remote patient monitoring. Its platform has the potential to reduce healthcare costs by decreasing unnecessary tests and hospitalizations. With a strong pipeline and a clear unmet need, CorVista Health represents a compelling opportunity in the diagnostics sector. The conviction score is driven by the large addressable market, the severity of the misdiagnosis problem, and the company's innovative approach, balanced against the typical risks of early-stage medical device development.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance or De Novo classification for CorVista System in coronary artery disease detection70% success
• Q3 2026Publication of pivotal clinical study data demonstrating diagnostic accuracy for heart failure80% success
• Q4 2026Strategic partnership with a major health system for commercial pilot and reimbursement60% success